Tempus AI, Inc.

Tempus AI, Inc.

63.43
USD
-1.33
(-2.05%)
-1.05EPS
14.92BMarket Cap
Mar 02Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.39
1.17
1.6
2
3.23
5.79
7.3
8.4
Basic EPS, GAAP
-0.88
-1.53
-1.85
-2.08
-1.59
-6.23
-1.41
-1.05
Free Cash Flow per Basic Share
-0.83
-1.37
-1.39
-1.16
-1.51
-1.76
-1.37
-0.76
Dividend per Share
0.03
0.04
0.04
0.04
0.03
0.05
- -
- -
Book Value per Share
-1.54
-3.11
-4.9
-6.85
-8.39
0.35
2.76
2.75
Tangible Book Value per Share
-1.89
-3.48
-5.22
-7.4
-8.96
-0.18
-1.87
-1.77
Basic Weighted Avg Shares
161
161
161
161
165
120
174
180
Sales/Revenue/Turnover
62
188
258
321
532
693
1,272
1,509
Operating Margin (%)
-193.02
-102.9
-94.52
-82.78
-36.87
-99.67
-19.88
-18.48
Depreciation Expense
15
23
24
30
33
37
102
105
Net Income, GAAP
-115
-210
-259
-290
-214
-706
-245
-189
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-185.23
-111.62
-100.52
-90.38
-40.26
-101.79
-19.27
-12.54
Working Capital
232
548
289
264
118
377
795
700
LT Debt
1
251
239
427
482
462
1,314
1,420
Total Equity
-254
-513
-807
-1,129
-1,382
56
491
500
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
-89.48
-37.55

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
13
12
12
LT Borrowings
1,233
1,361
1,351
LT Finance Leases
73
71
69
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
179
180
182
Market Capitalization
8,113
10,442
14,924

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,054
1,291
1,137
Cash, Cash Equivalents & STI
639
816
637
Accounts Receivable, Net
309
361
381
Inventories
52
54
54
Total Current Liabilities
318
391
436
Payables & Accruals
167
219
265
ST Debt
13
12
12
Deferred Revenue
89
103
98

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
157.53%
772.09%
Free Cash Flow
- -
3.32%
13.25%
Net Income, GAAP
- -
34.71%
-65.28%
Sales/Revenue/Turnover
- -
48.23%
83.41%
Total Cash Common Dividend
- -
-16.99%
-100%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
146
166
181
201
693
2025
256
315
334
367
1,272
2026
348
382
412
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.56
-6.86
-0.46
-0.08
-6.23
2025
-0.4
-0.25
-0.46
-0.3
-1.41
2026
-0.7
0.03
-0.08
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.07
- -
- -
0.05
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Eric Paul Lefkofsky
Full Time Employees
3,800
Sector
Technology services
Industry
Packaged software
Address
600 West Chicago Avenue Chicago IL United States 60654
IPO Date
Jun 14, 2024
Website
tempus.com
Business
Tempus AI, Inc. operates as an innovative healthcare technology firm, dedicated to transforming patient care through the application of artificial intelligence. The company specializes in delivering comprehensive genomic sequencing diagnostics, including next-generation sequencing, polymerase chain reaction profiling, and advanced molecular pathology testing to a broad spectrum of healthcare entities. These clients include medical providers, pharmaceutical manufacturers, biotechnology innovators, and research institutions. The organization provides a suite of advanced platforms such as Tempus Lens, designed for scientists to explore, access, and analyze de-identified clinical, molecular, and imaging data, and Tempus Hub, a streamlined desktop and mobile interface for managing test orders and patient results. Their offerings also encompass predictive algorithmic tests, like Algos and Next, tailored for oncology and other therapeutic areas, as well as Trials, a service that facilitates patient matching for clinical studies. Tempus AI generates revenue primarily through its genomic testing services, data licensing, and clinical trial solutions. The company notably expanded its reach by going public on Nasdaq in June 2024 under the ticker TEM. Recent strategic developments include the November 2024 acquisition of Ambry Genetics, a $600 million deal, and the formation of SB Tempus, an AI healthcare joint venture in Japan with SoftBank. In April 2025, Tempus AI, AstraZeneca, and Pathos AI announced multi-year agreements, including $200 million in data licensing and model development fees to Tempus, to co-develop a significant multimodal foundation model in oncology, building on an earlier 2021 partnership. Further collaborations in 2025 include a partnership with Illumina for genomic testing integration and research alliances with Northwestern University for Alzheimer's disease and the Institute for Follicular Lymphoma Innovation. Headquartered in Chicago, Illinois, Tempus AI was established in 2015 and remains at the forefront of leveraging large-scale multimodal data and AI to accelerate precision medicine, with a significant presence among U.S. oncologists and top biopharma companies.

Company News

  • Arizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening Studies

  • Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

  • Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer

  • SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

  • Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up

  • Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)

  • Tempus AI Surges on Earnings Beat, But Can the Rally Last?

  • TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside

  • Baron SMID Cap ETF Q3 2026 Contributors And Detractors

  • Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results

  • 3 Stocks to Watch Following Guidance Upgrades

  • Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge

  • Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript

  • Tempus AI Says It Is Uniquely Positioned

  • Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say

  • Tempus AI (TEM) Beats Q3 Earnings and Revenue Estimates

  • What Tempus AI (TEM) Said on Its Q3 Earnings Call

  • Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction

  • Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer

  • Tempus Reports Third Quarter 2026 Results